3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
PRETEXT I Hepatoblastoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Mouth Neoplasms
1
Melanoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
temsirolimus
×
90 days
×
Clear all
No trials found.